- Home
- SPCE vs IPHA Comparison
SPCE vs IPHA Comparison
Compare SPCE & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPCE
- IPHA
- Stock Information
- Founded
- SPCE 2017
- IPHA 1999
- Country
- SPCE United States
- IPHA France
- Employees
- SPCE N/A
- IPHA N/A
- Industry
- SPCE Transportation Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SPCE Consumer Discretionary
- IPHA Health Care
- Exchange
- SPCE Nasdaq
- IPHA Nasdaq
- Market Cap
- SPCE 133.5M
- IPHA 160.1M
- IPO Year
- SPCE N/A
- IPHA 2019
- Fundamental
- Price
- SPCE $3.14
- IPHA $2.24
- Analyst Decision
- SPCE Hold
- IPHA Strong Buy
- Analyst Count
- SPCE 6
- IPHA 1
- Target Price
- SPCE $9.54
- IPHA $11.00
- AVG Volume (30 Days)
- SPCE 2.8M
- IPHA 13.0K
- Earning Date
- SPCE 08-06-2025
- IPHA 09-11-2025
- Dividend Yield
- SPCE N/A
- IPHA N/A
- EPS Growth
- SPCE N/A
- IPHA N/A
- EPS
- SPCE N/A
- IPHA N/A
- Revenue
- SPCE $1,698,000.00
- IPHA $20,831,349.00
- Revenue This Year
- SPCE N/A
- IPHA $350.96
- Revenue Next Year
- SPCE $4,020.33
- IPHA $32.92
- P/E Ratio
- SPCE N/A
- IPHA N/A
- Revenue Growth
- SPCE N/A
- IPHA N/A
- 52 Week Low
- SPCE $2.18
- IPHA $1.29
- 52 Week High
- SPCE $8.19
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SPCE 45.08
- IPHA 59.62
- Support Level
- SPCE $2.92
- IPHA $2.22
- Resistance Level
- SPCE $3.08
- IPHA $2.32
- Average True Range (ATR)
- SPCE 0.17
- IPHA 0.11
- MACD
- SPCE -0.04
- IPHA 0.00
- Stochastic Oscillator
- SPCE 20.56
- IPHA 62.09
About SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.